Redefining pharmacovigilance: from compliance to competitive advantage
For decades, pharmacovigilance has been viewed primarily as a regulatory obligation — a necessary cost of bringing and keeping medicines on the market. Today, that mindset is outdated.
The traditional model: compliance first
Historically, pharmacovigilance focused on timely adverse event reporting, inspection readiness, regulatory submission accuracy, and risk minimisation. In this model, PV operated largely in isolation — a back-office function measured by adherence to timelines and audit outcomes. Success meant avoiding warning letters and maintaining marketing authorisation. While this framework ensured regulatory stability, it often limited pharmacovigilance to a cost centre rather than a value driver.
Four forces reshaping safety organisations
- Expanding regulatory expectations — proactive risk management, lifecycle benefit-risk evaluation, and robust real-world evidence integration.
- The explosion of data — safety signals now emerge from RWE, EHRs, literature, patient-reported outcomes, and wearables.
- Digital acceleration — AI, automation, and NLP transform case intake, signal detection, and literature screening.
- Trust as market currency — safety performance shapes prescribing decisions, regulatory relationships, and brand reputation.
The business case for strategic PV
Early signal detection and integrated safety analytics improve trial design and reduce the likelihood of costly late-stage failures. Proactive safety governance strengthens credibility with health authorities, facilitating smoother approvals. Automation reduces case processing time and cost per case while improving data consistency. A strong safety reputation differentiates products in competitive therapeutic areas and reduces corporate risk exposure — a key consideration for investors and M&A evaluations.
Pharmacovigilance in Georgia
An effectively integrated pharmacovigilance system is particularly essential for countries that lack sufficient resources, expertise, and infrastructure to ensure medicine safety. In Georgia, pharmaceutical companies are required to maintain their own pharmacovigilance systems, and some level of active safety monitoring is conducted — particularly within the private sector. Strengthening pharmacovigilance in Georgia requires improving reporting systems, increasing awareness among healthcare professionals and patients, investing in capacity building, and enhancing coordination between public health programmes and regulatory authorities.
Conclusion
Pharmacovigilance is no longer merely a regulatory compliance obligation — it has evolved into a strategic capability that protects patients, informs clinical decision-making, and strengthens stakeholder trust. In Georgia, with targeted investments and strategic reforms, pharmacovigilance can be transformed into a powerful tool — enhancing patient protection, supporting high-quality clinical trials, and positioning the country as a competitive participant in the global healthcare ecosystem.
Prepared by Paspigioni team: Marika Gergedava, MD and Nina Biblaia